Psychosis in Parkinson's disease.
Identifieur interne : 000B56 ( Ncbi/Checkpoint ); précédent : 000B55; suivant : 000B57Psychosis in Parkinson's disease.
Auteurs : Werner Poewe [Autriche]Source :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2003.
English descriptors
- KwdEn :
- Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Antipsychotic Agents (therapeutic use), Cholinesterase Inhibitors (therapeutic use), Clinical Trials as Topic, Diagnosis, Differential, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Humans, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Psychoses, Substance-Induced (diagnosis), Psychoses, Substance-Induced (drug therapy), Psychotic Disorders (diagnosis), Psychotic Disorders (drug therapy), Risk Factors.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Dopamine Agonists.
- chemical , therapeutic use : Antiparkinson Agents, Antipsychotic Agents, Cholinesterase Inhibitors, Dopamine Agonists.
- diagnosis : Parkinson Disease, Psychoses, Substance-Induced, Psychotic Disorders.
- drug therapy : Parkinson Disease, Psychoses, Substance-Induced, Psychotic Disorders.
- Clinical Trials as Topic, Diagnosis, Differential, Humans, Risk Factors.
Abstract
Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major antiparkinsonian drugs can induce psychosis in at-risk patients. Early drug-induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia.
DOI: 10.1002/mds.10567
PubMed: 14502660
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003708
- to stream PubMed, to step Curation: 003708
- to stream PubMed, to step Checkpoint: 003673
- to stream Ncbi, to step Merge: 000B56
- to stream Ncbi, to step Curation: 000B56
Links to Exploration step
pubmed:14502660Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Psychosis in Parkinson's disease.</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria. werner.poewe@uibk.ac.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University of Innsbruck, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2003">2003</date><idno type="RBID">pubmed:14502660</idno><idno type="pmid">14502660</idno><idno type="doi">10.1002/mds.10567</idno><idno type="wicri:Area/PubMed/Corpus">003708</idno><idno type="wicri:Area/PubMed/Curation">003708</idno><idno type="wicri:Area/PubMed/Checkpoint">003673</idno><idno type="wicri:Area/Ncbi/Merge">000B56</idno><idno type="wicri:Area/Ncbi/Curation">000B56</idno><idno type="wicri:Area/Ncbi/Checkpoint">000B56</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Psychosis in Parkinson's disease.</title><author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, University of Innsbruck, Innsbruck, Austria. werner.poewe@uibk.ac.at</nlm:affiliation><country xml:lang="fr">Autriche</country><wicri:regionArea>Department of Neurology, University of Innsbruck, Innsbruck</wicri:regionArea><wicri:noRegion>Innsbruck</wicri:noRegion><placeName><settlement type="city">Innsbruck</settlement><region nuts="2" type="region">Tyrol (Land)</region></placeName><orgName type="university">Université de médecine d'Innsbruck</orgName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2003" type="published">2003</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (adverse effects)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Antipsychotic Agents (therapeutic use)</term><term>Cholinesterase Inhibitors (therapeutic use)</term><term>Clinical Trials as Topic</term><term>Diagnosis, Differential</term><term>Dopamine Agonists (adverse effects)</term><term>Dopamine Agonists (therapeutic use)</term><term>Humans</term><term>Parkinson Disease (diagnosis)</term><term>Parkinson Disease (drug therapy)</term><term>Psychoses, Substance-Induced (diagnosis)</term><term>Psychoses, Substance-Induced (drug therapy)</term><term>Psychotic Disorders (diagnosis)</term><term>Psychotic Disorders (drug therapy)</term><term>Risk Factors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Antipsychotic Agents</term><term>Cholinesterase Inhibitors</term><term>Dopamine Agonists</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Parkinson Disease</term><term>Psychoses, Substance-Induced</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term><term>Psychoses, Substance-Induced</term><term>Psychotic Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Diagnosis, Differential</term><term>Humans</term><term>Risk Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major antiparkinsonian drugs can induce psychosis in at-risk patients. Early drug-induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia.</div></front></TEI><affiliations><list><country><li>Autriche</li></country><region><li>Tyrol (Land)</li></region><settlement><li>Innsbruck</li></settlement><orgName><li>Université de médecine d'Innsbruck</li></orgName></list><tree><country name="Autriche"><region name="Tyrol (Land)"><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B56 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 000B56 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Checkpoint
|type= RBID
|clé= pubmed:14502660
|texte= Psychosis in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:14502660" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |